Emergence of carbapenem-resistant and colistin-susceptible Enterobacter cloacae complex co-harboring bla
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ genetics
Carbapenems
/ pharmacology
Colistin
/ pharmacology
Drug Resistance, Bacterial
/ drug effects
Enterobacter cloacae
/ drug effects
Enterobacteriaceae Infections
/ microbiology
Humans
Imipenem
/ pharmacology
Japan
Meropenem
/ pharmacology
Microbial Sensitivity Tests
Phylogeny
Plasmids
Polymorphism, Single Nucleotide
beta-Lactamases
/ genetics
Carbapenem resistance
Colistin resistance
E. Asburiae
E. Xiangfangensis
Enterobacter cloacae complex
Mcr-9
blaIMP-1
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Apr 2020
16 Apr 2020
Historique:
received:
15
01
2020
accepted:
08
04
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
9
7
2020
Statut:
epublish
Résumé
The spread of Enterobacteriaceae producing both carbapenemases and Mcr, encoded by plasmid-mediated colistin resistance genes, has become a serious public health problem worldwide. This study describes three clinical isolates of Enterobacter cloacae complex co-harboring bla Thirty-two clinical isolates of E. cloacae complex non-susceptible to carbapenems were obtained from patients at 14 hospitals in Japan. Their minimum inhibitory concentrations (MICs) were determined by broth microdilution methods and E-tests. Their entire genomes were sequenced by MiSeq and MinION methods. Multilocus sequence types were determined and a phylogenetic tree constructed by single nucleotide polymorphism (SNP) alignment of whole genome sequencing data. All 32 isolates showed MICs of ≥2 μg/ml for imipenem and/or meropenem. Whole-genome analysis revealed that all these isolates harbored bla The mcr-9 is silently distributed among carbapenem-resistant E. cloacae complex isolates, of which are emerging in hospitals in Japan. To our knowledge, this is the first report of isolates of E. cloacae complex harboring both bla
Sections du résumé
BACKGROUND
BACKGROUND
The spread of Enterobacteriaceae producing both carbapenemases and Mcr, encoded by plasmid-mediated colistin resistance genes, has become a serious public health problem worldwide. This study describes three clinical isolates of Enterobacter cloacae complex co-harboring bla
METHODS
METHODS
Thirty-two clinical isolates of E. cloacae complex non-susceptible to carbapenems were obtained from patients at 14 hospitals in Japan. Their minimum inhibitory concentrations (MICs) were determined by broth microdilution methods and E-tests. Their entire genomes were sequenced by MiSeq and MinION methods. Multilocus sequence types were determined and a phylogenetic tree constructed by single nucleotide polymorphism (SNP) alignment of whole genome sequencing data.
RESULTS
RESULTS
All 32 isolates showed MICs of ≥2 μg/ml for imipenem and/or meropenem. Whole-genome analysis revealed that all these isolates harbored bla
CONCLUSION
CONCLUSIONS
The mcr-9 is silently distributed among carbapenem-resistant E. cloacae complex isolates, of which are emerging in hospitals in Japan. To our knowledge, this is the first report of isolates of E. cloacae complex harboring both bla
Identifiants
pubmed: 32299378
doi: 10.1186/s12879-020-05021-7
pii: 10.1186/s12879-020-05021-7
pmc: PMC7161257
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Carbapenems
0
Imipenem
71OTZ9ZE0A
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Meropenem
FV9J3JU8B1
Colistin
Z67X93HJG1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
282Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K07120
Organisme : Japan Society for the Promotion of Science
ID : 18K07121
Organisme : Japan Agency for Medical Research and Development
ID : 19fk0108061h0302
Organisme : Asahi Group Holdings
ID : AM227CH501
Organisme : Juntendo University
ID : 6119002
Références
Microbiologyopen. 2019 Apr;8(4):e00682
pubmed: 29974640
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3141-4
pubmed: 26883705
J Med Microbiol. 2017 Jul;66(7):874-883
pubmed: 28671537
Int J Antimicrob Agents. 2017 May;49(5):526-535
pubmed: 28163137
Clin Microbiol Infect. 2014 Sep;20(9):821-30
pubmed: 24930781
J Med Microbiol. 2017 Nov;66(11):1554-1561
pubmed: 28984232
J Antimicrob Chemother. 2015 Jul;70(7):2133-43
pubmed: 25900159
BMC Bioinformatics. 2013 Feb 21;14:60
pubmed: 23432962
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31209009
Front Microbiol. 2019 Aug 08;10:1753
pubmed: 31440216
Genome Announc. 2013 Dec 05;1(6):
pubmed: 24309736
Int J Antimicrob Agents. 2018 Jun;51(6):842-847
pubmed: 29371103
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172
Int J Antimicrob Agents. 2018 Sep;52(3):416-420
pubmed: 29807164
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5033-5
pubmed: 27216058
J Antimicrob Chemother. 2016 Aug;71(8):2340-2
pubmed: 27246233
J Antimicrob Chemother. 2017 Oct 1;72(10):2745-2749
pubmed: 29091227
mBio. 2019 May 7;10(3):
pubmed: 31064835
Infect Drug Resist. 2019 Sep 19;12:2979-2985
pubmed: 31571950
Emerg Infect Dis. 2016 Sep;22(9):1689-91
pubmed: 27322919
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559252
Curr Infect Dis Rep. 2017 Sep 11;19(11):38
pubmed: 28895051
Lancet Infect Dis. 2011 May;11(5):381-93
pubmed: 21530894
Clin Infect Dis. 2005 May 1;40(9):1333-41
pubmed: 15825037
J Clin Microbiol. 2017 Dec;55(12):3454-3465
pubmed: 28978685
mSphere. 2019 Sep 11;4(5):
pubmed: 31511372
Mol Microbiol. 2005 Oct;58(2):441-55
pubmed: 16194231
Antonie Van Leeuwenhoek. 2017 Oct;110(10):1281-1286
pubmed: 28204908
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
Infect Drug Resist. 2019 Apr 03;12:733-739
pubmed: 31118694
Ann Clin Microbiol Antimicrob. 2015 Nov 25;14:51
pubmed: 26607057